Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706574 | 0.92 | FAAH (0.35) | KDM4EFAAHGSK3BDYRK1A | |
| SCHEMBL16754291 | 0.88 | KDM4E (0.35) | KDM4EFAAHRAB9AKMT2AMEN1 | |
| SCHEMBL16776496 | 0.86 | KDM4E (0.40) | KDM4EFAAHRAB9AKMT2AMEN1 | |
| SCHEMBL19706066 | 0.86 | FAAH (0.35) | FAAHKMT2AMEN1GSK3BDYRK1A | |
| SCHEMBL19670259 | 0.86 | FAAH (0.35) | FAAHKMT2AMEN1GSK3BDYRK1A | |
| SCHEMBL19670616 | 0.85 | KDM4E (0.33) | KDM4EFAAHRAB9AKMT2AMEN1 | |
| SCHEMBL17618518 | 0.85 | PIK3CA (0.39) | KDM4EFAAHTP53L3MBTL1GSK3B | |
| SCHEMBL16754501 | 0.85 | FAAH (0.36) | KDM4EFAAHRAB9AKMT2AMEN1 | |
| SCHEMBL16754406 | 0.85 | TBK1 (0.35) | KDM4EFAAHRAB9AKMT2AMEN1 | |
| SCHEMBL19670501 | 0.84 | FAAH (0.35) | FAAHGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDM4E 950/4885FAAH 977/4885RAB9A 1471/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | KDM4E 950/4885FAAH 977/4885RAB9A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.